ACTUATE THERAPEUTICS INC (ACTU) Stock Price, Quote, News and Overview
NASDAQ:ACTU - Nasdaq - US0050831009 - Currency: USD
ACTU Quote, Performance and Key Statistics
NASDAQ:ACTU (3/7/2025, 8:03:29 PM)
6.95
+0.01 (+0.14%)
The current stock price of ACTU is 6.95 USD. In the past month the price decreased by -21.21%.
ACTU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ACTU
Company Profile
Actuate Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Worth, Texas and currently employs 11 full-time employees. The company went IPO on 2024-08-13. Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The firm is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. Its lead program, Elraglusib Injection, is an intravenous solution of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib Injection has been evaluated in a Phase I dose escalation study (Actuate-1801 Part 1) in 238 adult patients. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Company Info
ACTUATE THERAPEUTICS INC
1751 River Run, Suite 400
Fort Worth TEXAS US
Employees: 11
Company Website: https://actuatetherapeutics.com/
Phone: 18479864190
ACTUATE THERAPEUTICS INC / ACTU FAQ
What is the stock price of ACTUATE THERAPEUTICS INC today?
The current stock price of ACTU is 6.95 USD. The price increased by 0.14% in the last trading session.
What is the ticker symbol for ACTUATE THERAPEUTICS INC stock?
The exchange symbol of ACTUATE THERAPEUTICS INC is ACTU and it is listed on the Nasdaq exchange.
On which exchange is ACTU stock listed?
ACTU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACTUATE THERAPEUTICS INC stock?
7 analysts have analysed ACTU and the average price target is 20.4 USD. This implies a price increase of 193.53% is expected in the next year compared to the current price of 6.95. Check the ACTUATE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACTUATE THERAPEUTICS INC worth?
ACTUATE THERAPEUTICS INC (ACTU) has a market capitalization of 135.73M USD. This makes ACTU a Micro Cap stock.
How many employees does ACTUATE THERAPEUTICS INC have?
ACTUATE THERAPEUTICS INC (ACTU) currently has 11 employees.
What are the support and resistance levels for ACTUATE THERAPEUTICS INC (ACTU) stock?
ACTUATE THERAPEUTICS INC (ACTU) has a support level at 6.76. Check the full technical report for a detailed analysis of ACTU support and resistance levels.
Should I buy ACTUATE THERAPEUTICS INC (ACTU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACTU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACTU, evaluating the profitability, health, valuation and growth aspects
- ACTUATE THERAPEUTICS INC (ACTU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACTUATE THERAPEUTICS INC (ACTU) Sales and EPS estimates to see what analysts future expectations are.
- ACTUATE THERAPEUTICS INC (ACTU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACTUATE THERAPEUTICS INC (ACTU) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACTUATE THERAPEUTICS INC (ACTU) Stock Chart to make your own analysis
- ACTUATE THERAPEUTICS INC (ACTU) Latest news and press-releases to stay up to date.
Does ACTUATE THERAPEUTICS INC (ACTU) stock pay dividends?
ACTU does not pay a dividend.
What is the Price/Earnings (PE) ratio of ACTUATE THERAPEUTICS INC (ACTU)?
ACTUATE THERAPEUTICS INC (ACTU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.38).
What is the Short Interest ratio of ACTUATE THERAPEUTICS INC (ACTU) stock?
The outstanding short interest for ACTUATE THERAPEUTICS INC (ACTU) is 0.47% of its float. Check the ownership tab for more information on the ACTU short interest.
ACTU Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ACTU.
ACTU Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACTU. ACTU may be in some trouble as it scores bad on both profitability and health.
ACTU Financial Highlights
Over the last trailing twelve months ACTU reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS decreased by -22.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -319.6% | ||
| ROE | -850.65% | ||
| Debt/Equity | 0.08 |
ACTU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ACTU. The Buy consensus is the average rating of analysts ratings from 7 analysts.